EHTHNasdaqInsurance Agents, Brokers & ServiceFiscal year ends December 31
eHealth, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.57−0.02 (-3.67%)
Close on Oct 19, 2026
- Market cap
- $17.96M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
43.5%−55.8 pts over 5 years
Operating margin
12.0%+2.9 pts over 5 years
Net margin
7.2%−0.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.1% | +11.0% | -1.0% | +11.3% | |
| Gross profit | +15.5% | -15.8% | -16.1% | +2.6% | |
| Operating income | +182.1% | – | +4.5% | – | |
| Net income | +298.2% | – | -2.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 0.1% | 6.7% | 6.8% | |
| Return on assets | 0.3% | 5.1% | 3.3% | |
| Current ratio | 2.73 | 3.92 | 3.37 | |
| Debt to equity | – | – | 0.19 | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | – | 6.2× | |
| Capex to revenue | 1.0% | 1.3% | 0.4% | |
| Diluted shares | 18M | 27M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
eHealth generated $239.89M from operations and spent $10.51M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$239.89M
Used
$10.51M
Capital expenditure$10.51M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.2%
×Asset turnover0.46×
×Equity multiplier2.05×
=Return on equity, FY20256.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.2% | 0.46× | 2.05× | 6.8% |
| FY2024 | 1.9% | 0.47× | 1.90× | 1.7% |
| FY2023 | -6.2% | 0.41× | 1.77× | -4.5% |
| FY2022 | -21.9% | 0.36× | 1.62× | -12.7% |
| FY2021 | -19.4% | 0.49× | 1.38× | -13.2% |
| FY2020 | 7.8% | 0.65× | 1.31× | 6.7% |
| FY2019 | 13.2% | 0.86× | 1.42× | 16.1% |
| FY2018 | 0.1% | 0.63× | 1.35× | 0.1% |
| FY2017 | 13.3% | 0.81× | 0.87× | 9.4% |
| FY2016 | 0.2% | 1.74× | 0.45× | 0.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$40.04M
- Cash generatingOperating cash flow above zero-$25.35M
- Return on assets improvedROA up on the prior year0.9% → 3.5%
- Earnings backed by cashOperating cash flow above net income-$25.35M vs $40.04M
- Less leverageLong-term debt to assets fell5.9% → 8.9%
- Better liquidityCurrent ratio rose3.69 → 3.37
- No dilutionShare count did not rise29M → 30M
- Gross margin improvedGross margin up on the prior year39.15% → 43.46%
- More efficientAsset turnover rose0.48 → 0.48